New hope for hard-to-treat prostate cancer: experimental drug enters human testing
NCT ID NCT05997615
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 25 times
Summary
This early-stage study tests a new drug called VIR-5500 in people with advanced prostate cancer that has spread and is no longer controlled by standard therapies. The study has four parts, first testing the drug alone, then in combination with other prostate cancer medicines. The main goals are to check safety and to see if the drug can shrink tumors or lower PSA levels. About 390 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HORMONE-REFRACTORY PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Investigational Site Number: 100
RECRUITINGMelbourne, 3000, Australia
-
Investigational Site Number: 101
RECRUITINGSydney, 2010, Australia
-
Investigational Site Number: 250
RECRUITINGBarcelona, 08035, Spain
-
Investigational Site Number: 251
WITHDRAWNBarcelona, 08023, Spain
-
Investigational Site Number: 252
RECRUITINGMadrid, 28223, Spain
-
Investigational Site Number: 253
RECRUITINGPamplona, 31008, Spain
-
Investigational Site Number: 254
RECRUITINGMadrid, 28027, Spain
-
Investigational Site Number: 300
RECRUITINGLondon, SM2 5PT, United Kingdom
-
Investigational Site Number: 400
RECRUITINGSeattle, Washington, 98109, United States
-
Investigational Site Number: 401
RECRUITINGHouston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.